Horizon Therapeutics Public Limited Company

Headquarters: Dublin, Ireland

Founded: 2005

Employees: 1,890

CEO: Mr. Timothy P. Walbert

show_chart NASDAQ: HZNP

Market Cap

$23.64 Billion

USD as of April 1, 2022

history Market Cap History

Horizon Therapeutics Public Limited Company market capitalization over time

Evolution of Horizon Therapeutics Public Limited Company market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Horizon Therapeutics Public Limited Company

Detailed Description

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Wikipedia Introduction

Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. Horizon's drug portfolio is focused on treatments for thyroid eye disease (TED), gout, rare diseases, and inflammatory diseases. Horizon's portfolio includes Tepezza (teprotumumab), Krystexxa (pegloticase), Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), Rayos/Lodotra (prednisone), Vimovo (naproxen/esomeprazole magnesium), Buphenyl (sodium phenylbutyrate), Procysbi (cysteamine bitartrate), and Ravicti (glycerol phenylbutyrate). In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Source: Wikipedia, retrieved on March 31, 2022, 8:59 p.m.

Best-Selling Downloads

S&P 500 Companies Excel Download $29.90
Russell 3000 Companies Excel Download $99.90
580 Unicorn Startup Companies – Excel Spreadsheet $29.90
FTSE 350 Companies Excel Download $24.90
Top 1300 UK Companies [FTSE All-Share + FTSE AIM All-Share] – Excel Download $59.90
TSX Composite Companies Excel Download $19.90

Save tens of hours in 2 minutes!

Key People

Timothy P. Walbert (Chairman, President & CEO) Paul W. Hoelscher (CFO) Andy Pasternak (CBO) Jeffrey W. Sherman, M. D. (CMO)


Revenue: US$3.22 billion (2021 )

Net income: US$264 million (2014)

Stocks & Indices

Horizon Therapeutics Public Limited Company has the following listings and related stock indices.


Stock: FSX: HPR



Connaught House

1st Floor 1 Burlington Road

Dublin, 4


Phone: 353 1 772 2100